cyrilzakka/clinical-trials huggingface dataset:
Efficacy and Safety of the Distal Radial Approach

The aim of this non-inferiority trial is to determine if the distal radial access (DRA) during percutaneous coronary intervention (PCI) has an acceptable efficacy compared to the reference access through the conventional radial artery (TRA) with a lower rate of radial artery occlusion (RAO) in real life practice.

The conventional radial approach is the recommended vascular access for percutaneous coronary interventions. It is effective, feasible, but associated with a risk of occlusion of the radial artery.

The distal radial approach is proposed as a new approach to reduce complications and preserve the radial artery. However, few clinical trials in real life were conducted in North African patients.

This trial aims to evaluate the efficacy and safety of the distal radial approach versus the conventional radial approach.

This trial is a non-inferiority, randomized controlled trial with two parallel arms: distal radial approach and conventional radial approach. Two hundred and fifty patients scheduled for percutaneous coronary intervention will be included. The two main endpoints are the puncture success rate with a non-inferiority margin of 10% and the rate of 30-day occlusion of the punctured radial artery.

Secondary endpoints: catheterization success, crossover rate, procedure time, radial artery spasm, bleeding complications, QuickDASH score, pain score and operator satisfaction A single blind analysis will be led according to the per-protocol and intention-to-treat methods.

Avoiding occlusion of the puncture site allows to preserve the radial artery for subsequent coronary or cerebral percutaneous interventions as well as for coronary bypasses and hemodialysis fistulas. The results will provide the parameters related to the efficacy and safety of the distal radial approach, so improving clinical practice.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old.
* Hospitalized in the cardiology department of the military hospital of Tunis.
* elective Percutaneous coronary intervention performed by experienced operators or fellows trained in the proximal and distal radial approach

Non-inclusion criteria:

* not provided written informed consent
* both radial arteries were used for prior catheterization
* Under oral anticoagulation
* Having coronary bypass surgery
* Hemodynamic instability
* contra-indication to the radial approach:

  * Orthopedic surgery: amputation
  * Severe burns of both upper limbs.
  * Radial artery pulse not palpable, negative modified Allen test or Barbeau classification type D
  * Identified radial vascular anomaly: stenosis, fistula, tortuosity not allowing passage of the catheter

Exclusion Criteria:

* death within a short period of time after admission
* PCI by the same puncture site will be performed within 30 days after the first puncture
* lost to follow-up
Effects of Aerobic Training on Exercise Capacity in Patients With Advanced Cirrhosis 2

Cirrhosis is associated with a reduction in muscle mass and exercise capacity. This has an impact on morbidity and mortality. Regular aerobic exercise training is a proven effective therapy to improve exercise capacity in healthy and clinical populations. The effect of this training has not yet been evaluated in the decompensated cirrhosis patient population. The safety of this intervention also requires further study. Using a randomized controlled design, the investigators aim to determine the safety and efficacy of eight weeks of aerobic exercise training on aerobic capacity, functional performance, and muscle mass in decompensated cirrhosis patients.


Eligibility Criteria:
Inclusion Criteria:

* Age \>18 and ≤ 70 years
* Cirrhosis
* Child Pugh class B or C
* If required, primary or secondary variceal prophylaxis in place

Exclusion Criteria:

* Post-liver transplantation
* Hepatocelluar carcinoma beyond transplant criteria
* Active non-hepatocelluar carcinoma malignancy
* Significant cardiac disease
* Hemoglobin (\<80 g/L)
* Oxygen saturation at rest \<95%
* Known myopathy
* Chronic renal failure on dialysis
* Physical impairment making it impossible to ride an exercise bike or treadmill
* Orthopedic abnormality preventing exercise training
* HIV infection
* Patient unwilling to consent to study
Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age. The main area of interest in the study is the pattern of any vaginal bleeding that occurs.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.

Eligibility Criteria:
Inclusion Criteria:

* Women with intact uterus, regular menstrual cycles and no previous or current climacteric symptoms.

Exclusion Criteria:

* Pregnancy or lactation.
* Previous pelvic infections.
* Abnormal bleeding.
* Abnormal uterine cavity.
* Uterine polyps.
* Genital cancer.
* Liver diseases.
* Alcoholism or drug abuse.
Study on Clinical Features, Treatment Mode and Survival of Sarcoma

The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.

This study was a single-center retrospective clinical study, which retrospectively collected the clinical data of all eligible patients receiving chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgical treatment in Henan Tumor Hospital from June 1, 2012 to May 30, 2022. The efficacy, recurrence and survival of various treatments were collected.

Eligibility Criteria:
Inclusion Criteria:

No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes.

Complete follow-up data.

Exclusion Criteria:

No clear pathology. Incomplete follow-up data.
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.


Eligibility Criteria:
Inclusion Criteria:

* You have a diagnosis of non-small cell lung cancer.
* You have received no prior chemotherapy.
* You have at least one measurable lesion.
* You have an adequate performance status.
* You are at least 18 years of age.

Exclusion Criteria:

* You have previously received chemotherapy for your lung cancer.
* You have received radiation within the last 30 days.
* You have active infection or other serious condition.
* You have brain metastasis.
* You have recently lost a significant amount of weight.
Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities

The purpose of this study is to determine whether dynamic contrast enhanced MRI (DCE MRI) and high diffusion weighting MRI may be used to distinguish between favorable and unfavorable responses to therapy of glioblastoma multiforme. Imaging data will be correlated with histopathologic findings and clinical responses to radiation therapy with or without chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* The presence of a primary brain tumor that cannot be completely resected that requires radiation therapy with or without chemotherapy.

Exclusion Criteria:

* Patients who do not have a primary brain tumor or who are unable to tolerate the environment of the MRI scanner
Antibacterial Properties of Silicon Incorporated With Quaternary Ammonium Polyethylenimine Nanoparticles

The aim of this study is to evaluate the antibacterial activity of crosslinked quaternary ammonium polyethylenimine (PEI) nanoparticles incorporated at 1-2% w/w in a commercial soft liner material when compared to the commercial soft liner material.

The investigators' results in vitro showed a significant delay in bacterial growth.

Therefore, the investigators assume to have the same delay in vivo- on patients.


Eligibility Criteria:
Inclusion Criteria:

* patients post maxillectomy, who are using obturators

Exclusion Criteria:

* patients who are not using obturators
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy

1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center.
2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center

1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample
2. Collect data of Biomarker for pancreatic cancer
3. Compare with Big data and Cohort study in National cancer center
4. The number of subjects is changed by statistical consideration. 218-\>238

Eligibility Criteria:
Inclusion Criteria:

* Pathologically Confirmed Pancreatic Cancer Patients

Exclusion Criteria:

* Subjects who do not agree with the study
Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study

The purpose of this study is to prospectively evaluate acute and long term clinical results of orbital atherectomy (OA) with adjunctive drug coated balloon (DCB) angioplasty versus DCB angioplasty alone for treatment of Peripheral Artery Disease (PAD) in below the knee (BTK) lesions.


Eligibility Criteria:
Inclusion Criteria:

* Subject's age ≥ 18 years
* Rutherford Clinical Category 3 - 5
* Lesions \[except in-stent restenosis (ISR)\] of the distal popliteal (POP segment below the anatomical knee joint), anterior tibial, posterior tibial, tibial peroneal trunk, and peroneal arteries with ≥ 70 % diameter stenosis (DS) by angiography
* Presence of clearly visible calcification in two views (both sides of vessel at the same location) evaluated angiographically- \[Computerized tomography (CT) angio images may substitute to confirm distribution of calcium, if available as standard of care\]
* Length of calcium ≥ 25 % of total lesion length or ≥ 2 cm total length
* Target lesion length up to 20 cm

Exclusion Criteria:

* Subject or subject's legal representative is not willing to sign an Ethics Committee approved informed consent form or comply with the study protocol requirements
* Contraindicated by either device, per Instructions For Use
* Presence of inflow lesion (≥ 50 % DS) or inflow not successfully treated (≥ 50% DS and/or unresolved significant angiographic complication)
* Compromised outflow distal to the target lesion (≥ 70 % DS) or presence of lesion(s) or occlusion(s) located from 5 cm above the ankle to below the ankle joint space
* Subject has more than 2 target vessels requiring treatment
* The guide wire cannot be passed across the target lesion(s) and/or guide wire position distal to target lesion(s) outside vessel lumen
* Presence of significant (≥ 70 % DS) lesion(s) or occlusion(s) not meeting the study criteria which were not successfully treated during the index procedure (≥ 50 % DS and/or significant angiographic complication)
* Subject has planned amputation (including minor) of the index limb or previous major amputation of the contralateral limb
* Creatinine \> 2.5 mg/dL, unless on dialysis
* Subject has any significant medical condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study
* Subject is participating in an investigational drug or device study that has the potential to clinically interfere with the study outcome measures
* Subject is pregnant or planning to become pregnant within the study period
* Subject has an unresolved severe systemic infection
* Subject has an anticipated life span of less than one year
* Subjects with known hypersensitivity to paclitaxel or paclitaxel related compounds
* Subjects who cannot receive recommended anti-platelet and/or anticoagulant therapy
* Pre-dilatation of the target lesion prior to randomization and OA treatment
Evaluation of Result and Influence Factors on Composite Graft in Fingertip Amputation

Fingertips facilitate smooth motor activity, precise sensation, and the delicate movement of the hands and have an aesthetic function. Fingertip injuries are defined as injuries occurring distal to the insertion of the flexor and extensor tendons. These injuries are one of the most common trauma injuries presented in acute care settings, accounting for approximately 4.8 million emergency department visits per year in the United States.(1) Fingertip amputations may not constitute the majority among these fingertip injuries but can have a complex spectrum of injury. In these cases, the reconstruction methodologies focus on preserving the digital length, ensuring adequate soft tissue coverage, preserving the nail structure, achieving a well-contoured and painless fingertip, and restoring durable and sensate skin.

There are so many factor that influence the result of composite graft in distal finger tip amputation. Investigators will collected the data including the size of amputee , shape, level of amputation, mechanism of amputation, if hyperbaric oxygen therapy, operation procedures.

Fingertip amputations underwent

1. modified composite grafting with pulp Adipo-fascia advance flap
2. composite graft
3. revision amputation was collected in this study

Follow-up was arranged in out-patient department, including:

type of amputation ( Hirase classification, ) 2-point discrimination test, DASH(Disabilities of the Arm, Shoulder, and Hand) outcome measure, graft survival, pain evaluation with visual Analog scale other associated treatment such as hyperbaric oxygen therapy length of finger shortening at 6 month after operation

Eligibility Criteria:
Inclusion Criteria:

* February 1990 and June 2015, patients received composite graft in fingertip amputation

Exclusion Criteria:

* patients refused to participate the study
Comparison of Two Techniques for Maintaining Range of Motion

Flexibility is a measurable physical capacity considered a key component of physical fitness. Poor flexibility is usually attributed to excessive tension exerted by the antagonist muscles of the movement and supported by weak scientific evidence, static stretching is considered as the most effective intervention in the promotion of muscle extensibility, in attempting to improve mobility.

Flexibility is a measurable physical capacity considered as a key component of physical fitness thereby contributing to the health and performance of joints and the musculoskeletal system. In recent years, there has been increasing evidence that muscle weakness is a major factor behind reduced mobility. Consequently, training muscle contractility is likely to improve mobility . Regardless of terminology and of the quality of supporting evidence, stretching emerges as an intervention that elongates the tissues in attempting to improve mobility . Shortening lengthens the tissue on two out of three axes, while stretching only lengthens the tissue on one axis out of three . All training, including movement, is, by definition, training of shortening and stretching cycles (SSCs). Ergo, resistance training is also, inherently, one way to elongate . Strength training is an active, voluntary, dynamic form of stretching. Indeed, strength training is dynamic stretching. Often, strength training is performed against external resistances, but this is not mandatory. Moreover, strength training has been shown to improve mobility in sedentary adults , .

Eligibility Criteria:
Inclusion Criteria:

* Both male and female
* Age between 18-25
* Recreationally active individuals (all kind of sports, gym, and outdoor leisure activities)

Exclusion Criteria:

* Individuals with any physiological or pathological problem
* Older age individuals
* Individuals that had hamstring injury in past 6 months
* Individuals that had quadriceps injury in past 6 months
* Individuals that had any lower limb injury in past 6 months
* Individuals involved in any other studies.
* Individuals involved in other WBV related study.
* Sedentary lifestyle individuals
Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies

The purpose of this study is to attempt to obtain an on-treatment biopsy in participants with non-small cell lung cancer who are receiving standard treatment with a drug that targets the PD-1 or PD-L1 protein.


Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed newly diagnosed or recurrent advanced Non Small Cell Lung Cancer/NSCLC that is PI-L1 high by immunohistochemistry (PD-L1 \>/= 50%)
* Intended treatment with a PD-(L)1 inhibitor
* Age \>/= 18 years
* Karnofsky Performance Status \>/= 70% and medically fit to undergo a biopsy procedure

Exclusion Criteria:

* Any medical condition or any sites of disease that would preclude a biopsy
* Pregnant or breastfeeding women
* Cognitively impairment affecting ability to understand and provide informed consent
* Prior PD-(L)1 blockade treatment
* Chemotherapy within 6 months prior to enrollment
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients

A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained with SB773812, and to accurately interpret future D2 RO results from either PET or SPECT studies with new compounds.


Eligibility Criteria:
Inclusion criteria:

* Not pregnant or becoming pregnant during the study.
* No abnormality in clinical examination, clinical laboratory test or ECG.
* Not taking drugs
* Patients with schizophrenia, schizophreniform disorder or schizoaffective disorders.
* Patients with at least 1 month antipsychotic monotherapy with either risperidone, olanzapine or clozapine.
* Healthy volunteers with no neurological or psychiatric illness.

Exclusion criteria:

* Have received other antipsychotic during the last month or neuroleptics during the last year.
* If you have taken part in investigations you should not receive a radiation dose of more than 10 mSv over any 3 year period.
* History of bleeding disorder or are taking medication that affects blood clotting
* History of substance dependence (except nicotine)
* Claustrophobia
* Gross head deformity.
* Unable to lie still in the PET or SPECT camera for 1 hour and a half.
* The presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies.
Preventive Effect of H.pylori Eradication on Osteoporosis

In this study, the investigators observed the long-term incidence rate of osteoporosis in patients who received Helicobacter pylori eradication and examined differences by age and sex.

In this study, the investigators observed the long-term incidence rate of osteoporosis in patients who received Helicobacter pylori eradication and examined differences by age and sex. In addition, the investigators will analyze the correlation between the incidence of osteoporosis by comparing confounding factors such as body mass index, steroid use, and proton pump inhibitor use as well as the eradication status of H. pylori.

Eligibility Criteria:
Inclusion Criteria:

ㆍPatients tested Helicobacter pylori status

Exclusion Criteria:

ㆍPatients aged \< 20 years ㆍPatients with unknown Helicobacter pylori bone density status ㆍPatients with with a history of gastric cancer ㆍPatients with prior Helicobacter pylori eradication therapy ㆍPatients with a history of osteoporosis
Fuzzy AI Using VR for Collision Prevention

The purpose of this study is to develop and test a VR training system that integrates GFT AI with virtual obstacle scenarios that, when compared to a sham-VR training system, is hypothesized to increase neuromechanical and perceptual-motor fitness, decrease collision frequency and impact forces for soccer athletes, during a single training session and also when assessed at approximately 1 week and 1 month following training.

Player collisions cause over 70% of concussion injuries in contact sports, in addition to 50% of lower extremity injuries and 40% of catastrophic knee ligament injuries. The majority of these collisions are unanticipated, and associated with reduced neuromechanical and perceptual-motor fitness underlying an athlete's adaptability to on-field conditions. Thus, training collision anticipation necessitates a method that taps into neuromechanical and perceptual-motor fitness. Virtual reality (VR) is a tool that can target these mechanisms, while providing a safe, well-controlled environment for assessment and training. The current proposal innovates on VR with the integration of genetic fuzzy tree (GFT) artificial intelligence (AI) to drive scenario configuration designed to target modifiable mechanisms and tailored to the individual athlete's performance capabilities, for the optimization of behavior modification and skill transfer. The current study will examine test a GFT AI-driven VR collision anticipation training compared to a sham-VR training system in healthy soccer athletes.

Eligibility Criteria:
Inclusion Criteria:

* healthy
* varsity high school or collegiate soccer athlete

Exclusion Criteria:

* unable to participate in soccer
* history of congenital or acquired cognitive, ophthalmologic, or neurological disorders including developmental delay, brain tumor, stroke, or known peripheral or central vestibular disorders
* patients who have begun anti-depressant, stimulant or anti-seizure medications for treatment of their symptoms or for other, unrelated reasons within two months of testing will be excluded from testing